Format

Send to

Choose Destination
J Biol Chem. 2014 Jun 6;289(23):15969-78. doi: 10.1074/jbc.M114.564252. Epub 2014 Apr 22.

Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.

Author information

1
From the Division of Urological Cancers, Lund University, SE-205 02 Malmö, Sweden.
2
the Division of Organic Chemistry, Lund University, SE-221 00 Lund, Sweden.
3
the Department of Biochemistry and Structural Biology, Lund University, SE-221 00 Lund, Sweden, and.
4
the Maimonides Institute for Research in Biomedicine of Cordoba, Reina Sofia University Hospital, University of Córdoba, 14004 Córdoba, Spain.
5
From the Division of Urological Cancers, Lund University, SE-205 02 Malmö, Sweden, rebecka.hellsten@med.lu.se.

Abstract

The transcription factor STAT3 is constitutively active in several malignancies including castration-resistant prostate cancer and has been identified as a promising therapeutic target. The fungal metabolite galiellalactone, a STAT3 signaling inhibitor, inhibits the growth, both in vitro and in vivo, of prostate cancer cells expressing active STAT3 and induces apoptosis of prostate cancer stem cell-like cells expressing phosphorylated STAT3 (pSTAT3). However, the molecular mechanism of this STAT3-inhibiting effect by galiellalactone has not been clarified. A biotinylated analogue of galiellalactone (GL-biot) was synthesized to be used for identification of galiellalactone target proteins. By adding streptavidin-Sepharose beads to GL-biot-treated DU145 cell lysates, STAT3 was isolated and identified as a target protein. Confocal microscopy revealed GL-biot in both the cytoplasm and the nucleus of DU145 cells treated with GL-biot, appearing to co-localize with STAT3 in the nucleus. Galiellalactone inhibited STAT3 binding to DNA in DU145 cell lysates without affecting phosphorylation status of STAT3. Mass spectrometry analysis of recombinant STAT3 protein pretreated with galiellalactone revealed three modified cysteines (Cys-367, Cys-468, and Cys-542). Here we demonstrate with chemical and molecular pharmacological methods that galiellalactone is a cysteine reactive inhibitor that covalently binds to one or more cysteines in STAT3 and that this leads to inhibition of STAT3 binding to DNA and thus blocks STAT3 signaling without affecting phosphorylation. This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.

KEYWORDS:

Anticancer Drug; Cancer Therapy; Prostate Cancer; STAT3; Small Molecule

PMID:
24755219
PMCID:
PMC4047371
DOI:
10.1074/jbc.M114.564252
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center